News | Ventricular Assist Devices (VAD) | September 12, 2019

CorWave Presents First Successful In Vivo 60-day Study of Neptune LVAD

Data was reported at the 46th Annual Conference of the European Society for Artificial Organs

CorWave Presents First Successful In Vivo 60-day Study of Neptune LVAD

September 12, 2019 — CorWave announced successful completion of its first 60-day preclinical study to evaluate its Neptune left ventricular assist device (LVAD). The results were presented at the 46th Annual Conference of the European Society for Artificial Organs (ESAO), Sept. 8-12 in Hannover, Germany.

Trevor Snyder, Ph.D., senior director, translational and clinical research at CorWave, delivered an oral presentation, “CorWave LVAD: A physiologic, pulsatile-flow wave membrane pump.”

CorWave previously reported on the successful completion of 30-day follow-up of an earlier in vivo study. The final results of the 60-day experience, presented at the ESAO conference, confirm the CorWave pump’s ability to provide chronic circulatory support with outstanding hemocompatibility.

The CorWave technology features a physiologic design enabled by its unique undulating membrane. Among other advantages, the membrane is able to generate a natural pulse, replicating the blood flow and pressure characteristics of the patient’s native heart. CorWave’s membrane pump technology is being developed to reduce complications associated with current devices and improve the care of patients with heart failure. 

For more information: www.corwave.com

Related Content

Videos | Hemodynamic Support Devices | September 22, 2019
There was a 77 percent increase in survival in cardiogenic shock patients treated using a new protocol in the...
The Abiomed Impella percutaneous heart pump during a procedure at Henry Ford Hospital.

The Abiomed Impella percutaneous heart pump during a procedure at Henry Ford Hospital.

Podcast | Hemodynamic Support Devices | May 02, 2019
This podcast is a discussion with ...
Illustration showing the venous implantation route and where the inlet and outflow ports are when the Abiomed Impella RP is placed in the right side of the heart. The  Impella RP catheter is used for right heart hemodynamic support.

Illustration showing the venous implantation route and where the inlet and outflow ports are when the Impella RP is placed in the right side of the heart. 

Feature | Hemodynamic Support Devices | March 26, 2019 | Perwaiz Meraj, M.D. FACC and Uma Chandrasekaran, Ph.D.
Right heart failure (RHF) is a syndrome characterized by the inability of the right ventricle (RV) to support optimal
The Abiomed Impella RP had higher than expected mortality in its post approval study, much higher than in its pre-market approval study. The vendor and the FDA believe this might be due to poor patient selection and implanting the device too late to aid the patient.

The Abiomed Impella RP had higher than expected mortality in its post-approval study, much higher than in its pre-market approval study. The vendor and the FDA believe this might be due to poor patient selection and implanting the device too late to aid the patient.

Feature | Hemodynamic Support Devices | February 05, 2019 | Dave Fornell, Editor
The U.S.
Overlay Init